NR 566 ADVANCED PHARMACOLOGY CARE OF THE FAMILY
MIDTERM EXAM 2026/2027 | Rated A | Latest Chamberlain
College Guide | Pass Guaranteed
Total Questions: 75
Alignment: Chamberlain College of Nursing NR566 Curriculum, AANP/FNP
Certification Pharmacology Guidelines, Evidence-Based Prescribing Practices
2026/2027
Pharmacokinetics, Pharmacodynamics & Prescribing Principles
Q1: A 45-year-old patient with normal renal and hepatic function is started on a new
medication with half-life of 12 hours. Approximately how many days are needed to
reach steady-state concentration?
A. 1 day
B. 2.5 days [CORRECT]
C. 5 days
D. 10 days
Correct Answer: B
Rationale: Steady-state is reached after approximately 5 half-lives (5 × 12 hours = 60
hours = 2.5 days). At steady-state, drug elimination equals drug administration, and
plasma concentrations plateau. 1 day (A) is only 2 half-lives (75% of steady-state), while
5 days (C) and 10 days (D) exceed necessary time.
,Q2: A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a UTI.
The FNP recognizes this combination requires careful monitoring because:
A. Sulfonamides increase warfarin metabolism
B. Sulfonamides inhibit CYP2C9, increasing warfarin levels and bleeding risk [CORRECT]
C. Warfarin reduces sulfonamide absorption
D. This combination has no significant interaction
Correct Answer: B
Rationale: Sulfonamides (including TMP-SMX) inhibit CYP2C9, the primary enzyme
metabolizing S-warfarin (the more potent enantiomer). This increases warfarin levels,
INR, and bleeding risk. The interaction requires more frequent INR monitoring and
potential warfarin dose reduction. Sulfonamides don't increase metabolism (A) or
reduce absorption (C).
Q3: A drug with narrow therapeutic index requires:
A. Once-yearly monitoring
B. Careful titration and frequent monitoring of plasma levels due to small margin
between effective and toxic doses [CORRECT]
C. No dose adjustments for renal impairment
D. Can be safely given in loading doses without risk
Correct Answer: B
,Rationale: Narrow therapeutic index (NTI) drugs (digoxin, lithium, phenytoin, warfarin,
aminoglycosides) have small safety margin between minimum effective concentration
and toxic concentration. They require careful monitoring, therapeutic drug monitoring,
and individualized dosing. Renal impairment (C) and loading doses (D) are particularly
dangerous with NTI drugs.
Q4: A patient is prescribed a medication that is a substrate of CYP3A4. Which food/herb
should be avoided due to significant interaction?
A. Milk
B. Grapefruit juice [CORRECT]
C. Green tea
D. Chamomile tea
Correct Answer: B
Rationale: Grapefruit juice (and grapefruit) inhibits intestinal CYP3A4 and
P-glycoprotein, increasing bioavailability of many CYP3A4 substrates (statins, calcium
channel blockers, immunosuppressants). The effect can persist 24-72 hours after
consumption. Milk (A), green tea (C), and chamomile (D) don't have significant CYP3A4
effects.
Q5: A patient with renal impairment requires dose adjustment for which medication?
A. Lorazepam (metabolized by hepatic glucuronidation)
B. Metformin (renally excreted unchanged) [CORRECT]
C. Ibuprofen (hepatically metabolized)
, D. Prednisone (converted to active metabolite in liver)
Correct Answer: B
Rationale: Metformin is excreted unchanged by kidneys; eGFR <30 contraindicates use,
and dose reduction is needed for eGFR 30-45. Lorazepam (A), ibuprofen (C), and
prednisone (D) are primarily hepatically metabolized and don't require renal adjustment,
though active metabolites may accumulate in advanced renal failure.
Q6: A medication with high first-pass effect:
A. Has high oral bioavailability
B. Is extensively metabolized by the liver before reaching systemic circulation
[CORRECT]
C. Requires lower IV doses than oral doses
D. Is best administered orally for maximum effect
Correct Answer: B
Rationale: First-pass (presystemic) metabolism occurs when drugs absorbed from GI
tract travel via portal vein to liver before systemic circulation. High first-pass drugs
(nitroglycerin, morphine, propranolol, lidocaine) have low oral bioavailability and often
require alternative routes. IV doses are lower than oral (C is opposite), and oral
administration (D) is often ineffective.
Q7: A patient on a beta-blocker develops bronchospasm. The pharmacodynamic
explanation is:
A. Beta-1 blockade increasing heart rate
MIDTERM EXAM 2026/2027 | Rated A | Latest Chamberlain
College Guide | Pass Guaranteed
Total Questions: 75
Alignment: Chamberlain College of Nursing NR566 Curriculum, AANP/FNP
Certification Pharmacology Guidelines, Evidence-Based Prescribing Practices
2026/2027
Pharmacokinetics, Pharmacodynamics & Prescribing Principles
Q1: A 45-year-old patient with normal renal and hepatic function is started on a new
medication with half-life of 12 hours. Approximately how many days are needed to
reach steady-state concentration?
A. 1 day
B. 2.5 days [CORRECT]
C. 5 days
D. 10 days
Correct Answer: B
Rationale: Steady-state is reached after approximately 5 half-lives (5 × 12 hours = 60
hours = 2.5 days). At steady-state, drug elimination equals drug administration, and
plasma concentrations plateau. 1 day (A) is only 2 half-lives (75% of steady-state), while
5 days (C) and 10 days (D) exceed necessary time.
,Q2: A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a UTI.
The FNP recognizes this combination requires careful monitoring because:
A. Sulfonamides increase warfarin metabolism
B. Sulfonamides inhibit CYP2C9, increasing warfarin levels and bleeding risk [CORRECT]
C. Warfarin reduces sulfonamide absorption
D. This combination has no significant interaction
Correct Answer: B
Rationale: Sulfonamides (including TMP-SMX) inhibit CYP2C9, the primary enzyme
metabolizing S-warfarin (the more potent enantiomer). This increases warfarin levels,
INR, and bleeding risk. The interaction requires more frequent INR monitoring and
potential warfarin dose reduction. Sulfonamides don't increase metabolism (A) or
reduce absorption (C).
Q3: A drug with narrow therapeutic index requires:
A. Once-yearly monitoring
B. Careful titration and frequent monitoring of plasma levels due to small margin
between effective and toxic doses [CORRECT]
C. No dose adjustments for renal impairment
D. Can be safely given in loading doses without risk
Correct Answer: B
,Rationale: Narrow therapeutic index (NTI) drugs (digoxin, lithium, phenytoin, warfarin,
aminoglycosides) have small safety margin between minimum effective concentration
and toxic concentration. They require careful monitoring, therapeutic drug monitoring,
and individualized dosing. Renal impairment (C) and loading doses (D) are particularly
dangerous with NTI drugs.
Q4: A patient is prescribed a medication that is a substrate of CYP3A4. Which food/herb
should be avoided due to significant interaction?
A. Milk
B. Grapefruit juice [CORRECT]
C. Green tea
D. Chamomile tea
Correct Answer: B
Rationale: Grapefruit juice (and grapefruit) inhibits intestinal CYP3A4 and
P-glycoprotein, increasing bioavailability of many CYP3A4 substrates (statins, calcium
channel blockers, immunosuppressants). The effect can persist 24-72 hours after
consumption. Milk (A), green tea (C), and chamomile (D) don't have significant CYP3A4
effects.
Q5: A patient with renal impairment requires dose adjustment for which medication?
A. Lorazepam (metabolized by hepatic glucuronidation)
B. Metformin (renally excreted unchanged) [CORRECT]
C. Ibuprofen (hepatically metabolized)
, D. Prednisone (converted to active metabolite in liver)
Correct Answer: B
Rationale: Metformin is excreted unchanged by kidneys; eGFR <30 contraindicates use,
and dose reduction is needed for eGFR 30-45. Lorazepam (A), ibuprofen (C), and
prednisone (D) are primarily hepatically metabolized and don't require renal adjustment,
though active metabolites may accumulate in advanced renal failure.
Q6: A medication with high first-pass effect:
A. Has high oral bioavailability
B. Is extensively metabolized by the liver before reaching systemic circulation
[CORRECT]
C. Requires lower IV doses than oral doses
D. Is best administered orally for maximum effect
Correct Answer: B
Rationale: First-pass (presystemic) metabolism occurs when drugs absorbed from GI
tract travel via portal vein to liver before systemic circulation. High first-pass drugs
(nitroglycerin, morphine, propranolol, lidocaine) have low oral bioavailability and often
require alternative routes. IV doses are lower than oral (C is opposite), and oral
administration (D) is often ineffective.
Q7: A patient on a beta-blocker develops bronchospasm. The pharmacodynamic
explanation is:
A. Beta-1 blockade increasing heart rate
